Riskpilot← Back to searchSign inGet full accessARTS BIOLOGICS A/S
A/SIn liquidationCVR 33861605Ole Maaløes Vej 3Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 2011— employees
Revenue 2015
DKK -247K
-71% vs 2014
EBITDA margin
100.0%
+71% vs 2014
Equity ratio
-495.5%
Financial strength
Net profit 2015
DKK -240K
+72% vs 2014
| Revenue | DKK -247K | -71% |
| EBITDA | DKK -247K | +71% |
| Net profit | DKK -240K | +72% |
| Total assets | DKK 76K | -41% |
| Equity | DKK -376K | -175% |
| Employees | — | — |
Legal name
ARTS BIOLOGICS A/S
CVR number
33861605
Legal form
Aktieselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
22. juli 2011
Share capital
DKK 875.791
Employees
—
VAT registered
No
Audit selected
No
Last report
2015-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Ole Maaløes Vej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 |
|---|---|---|---|---|
| Revenue | -9.003 | -505 | -854 | -247 |
| Staff expenses | -3.124 | -22 | -0 | -0 |
| EBITDA | -12.127 | -483 | -854 | -247 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -12.127 | -483 | -854 | -247 |
| Net financials | 2 | -101 | -0 | -10 |
| Profit before tax | -9.625 | -583 | -855 | -257 |
| Tax | 1.250 | -115 | -13 | -18 |
| Net profit | -10.875 | -469 | -841 | -240 |
| Item | 2012 | 2013 | 2014 | 2015 |
|---|---|---|---|---|
| Total assets | 2.449 | 177 | 128 | 76 |
| Equity | 523 | 55 | -137 | -376 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 1.926 | 123 | 265 | 452 |
| Total debt | 1.926 | 123 | 265 | 452 |
EBITDA margin
-24740700.0%
This company
15.8%
Market median
-156586809% vs market
20122015
Equity ratio
-495.5%
This company
38.2%
Market median
-1397% vs market
20122015
Return on equity
-23954700.0%
This company
18.4%
Market median
-130188687% vs market
20122015
Net profit margin
-23954700.0%
This company
8.1%
Market median
-295737137% vs market
20122015
Asset turnover
-3.26×
This company
1.12×
Market median
-391% vs market
20122015
Debt / equity
1.20×
This company
0.62×
Market median
-94% vs market
20122015
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2011-07-22 – 2012-12-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
PH Chief Executive Officer | Chief Executive Officer | 2011 – 2013 |
GM Chief Executive Officer | Chief Executive Officer | 2013 – 2016 |
| Name | Role | Member since |
|---|---|---|
| Former (7) | ||
| Board of Directors | 2011 – 2016 | |
| Board of Directors | 2011 – 2011 | |
| Board of Directors | 2011 – 2011 | |
| Board of Directors | 2011 – 2016 | |
| Board of Directors | 2011 – 2016 | |
| Board of Directors | 2011 – 2012 | |
| Chairman | 2011 – 2016 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ARTS BIOLOGICS A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Hviid Nordkild | Chief Executive Officer | 0 companies |
| Gert Mads Bolwig | Chief Executive Officer | 0 companies |
| Friedrich Hillebrand | Board of Directors | 0 companies |
| Hasse Olesen | Board of Directors | 0 companies |
| Jens Harpøth Zilstorff | Board of Directors | 0 companies |
| Terje Kalland | Board of Directors | 0 companies |
| Per Falholt | Board of Directors | 0 companies |
| William John Henry | Board of Directors | 0 companies |
| David Carl Christian von Kauffmann | Chairman | 0 companies |